Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …

Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

Background Pulmonary arterial hypertension is characterized by pulmonary vascular
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

The response of immune cells in cardiac injury is divided into three continuous phases:
inflammation, proliferation and maturation. The kinetics of the inflammatory and proliferation …

The European Pediatric Pulmonary Vascular Disease Network is a registered, non-profit
organization that strives to define and develop effective, innovative diagnostic methods and …

Background In pulmonary arterial hypertension (PAH), there are no data comparing initial
triple oral therapy with initial double oral therapy. Objectives TRITON (The Efficacy and …

Pulmonary hypertension (PH) is characterized by pulmonary artery remodeling that can
subsequently culminate in right heart failure and premature death. Emerging evidence …

In the last few months, the number of cases of a new coronavirus-related disease (COVID-
19) rose exponentially, reaching the status of a pandemic. Interestingly, early imaging …